Dr. Gail Roboz recently joined the Medscape InDiscussion podcast, an audio series for healthcare professionals, for an in-depth dialogue regarding acute myeloid leukemia (AML) with colleagues from the MD Anderson Cancer Center in Houston, Texas. In episode 1, they break down a subtype of AML called APL, or acute promyelocytic leukemia, including signs and symptoms,…
When Greg Tanenbaum’s beloved grandfather, known as Poppy, was dealt an acute myeloid leukemia (AML) diagnosis and an estimated 48 hours to live in January of 2017, Greg and his family were devastated. Poppy was not only Greg’s grandfather; he was also Greg’s best friend and number one fan, present at all sporting events and…
Our Leukemia Program researchers and physicians made a huge splash at this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, an educational gathering of over 25,000 clinicians and scientists from around the world who are working to conquer blood disease. Our team was involved in over 40 study abstracts presented at the meeting,…
In the past few weeks, devastating hurricanes and earthquakes have forced people out of their homes and away from their cancer care facilities, highlighting a need for better education and preparedness surrounding the medical consequences of natural disasters. Emergency situations such as a hurricane, earthquake, blizzard, flood, or blackout, are unpreventable and can drive a…
On August 30, 2017, the United States Food and Drug Administration (FDA) approved the cell-based gene therapy Kymriah for treatment of children and young adults with a certain form of acute lymphoblastic leukemia (ALL), the most common childhood cancer in America. The approval greenlights the first gene therapy to be made available in the United…
The United States Food and Drug Administration (FDA) has approved CPX-351, a combination of chemotherapy drugs daunorubicin and cytarabine also known as Vyxeos, for treatment of two types of high-risk acute myeloid leukemia (AML). Clinical trial participants with newly diagnosed therapy-related AML (t-AML) and those with AML accompanied by myelodysplasia-related changes (AML-MRC) demonstrated increased life…
This Fourth of July holiday, we’re not only celebrating the red, white and blue that honors the independence and freedom of our country, but also freedom from cancer and the cancer “blues.” Feeling this sense of freedom may mean that you’re cancer-free or that you’re unwilling to let a cancer diagnosis define you. To be…
Dr. Gail J. Roboz is the principal investigator for a new immunotherapy clinical trial at Weill Cornell Medicine and NewYork-Presbyterian for people with acute myeloid leukemia (AML). The clinical trial is evaluating engineered CAR-T cells, UCART123, that have been specially engineered in the laboratory to be able to target a molecule on the surface of leukemia cells called CD123. It is…
In the summer of 2015, Weill Cornell Medical College and Cellectis, a French pharmaceutical company, announced a translational research collaboration for a new allogeneic chimeric antigen receptor T cell therapy called UCART123. This “off-the-shelf” product is a directed immunotherapy for patients with acute myeloid leukemia (AML), an aggressive blood cancer. T cells are harvested from…
Dr. Ellen Ritchie recently participated in an OncLive discussion on the latest modifications to the World Health Organization (WHO) classification of Myelodysplastic Syndromes (MDS). WHO classification is the standard diagnostic system utilized by medical institutions worldwide, including here at Weill Cornell Medicine. Recent advances in our understanding of the biological course of MDS have warranted revision…
December is an exciting month here at the Leukemia Program, as each year, our doctors and researchers are invited to attend and present their work at the annual meeting of the American Society of Hematology (ASH). This important meeting provides the opportunity to network with thousands of hematology specialists from all over the world. This…
Dr. Gail Roboz on ABC talks about “taking a chance on something new.” [go]
Earlier this week the U.S. News and World Report released their annual survey of “Best Hospitals”. NewYork-Presbyterian one of the country’s largest and most comprehensive hospitals was ranked New York’s No. 1 hospital for the 16th year in a row, and No. 6 ranked hospital in all of the United States. Dr. Augustine M.K. Choi,…
https://www.youtube.com/watch?v=GjOlIfrQKvI Gail Roboz, MD from Weill Cornell Medicine discusses minimal residual disease (MRD) found in acute myeloid leukemia (AML) patients. According to Dr Roboz the biology of the remaining leukemia cells may not be similar to the bulk disease that was eliminated with initial therapy. Currently there are efforts to characterize and quantify the remaining…
Friday, July 1, 2016 In many ways, it’s a science success story: 8-year-old boy with a rare form of brain cancer is treated by one of the world’s leading experts in the disease, who collaborates with a pioneering precision medicine institute to sequence his cancer and create a first-of-its-kind tumor model replica in the lab,…
Dr. Gail J. Roboz appeared as a guest on Fox 24’s News Talk Central to discuss the latest research, clinical trials and breakthroughs to be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. Please view the WGXA-FOX 24 segment “One of the most important things coming out of this meeting is that…
https://youtu.be/py5lWteQQR8 Ellen Ritchie, M.D., assistant professor of clinical medicine, joins OncLive in a discussion on the current best practices in the management of myelodysplastic syndrome and how the latest research is likely to impact the field. “I think it’s very important when we talk to patients about MDS that we talk about the broad spectrum of…
This clinical study is aimed at men and women with a diagnosis of: Chronic Neutrophilic Leukemia (CNL), Chronic Myelomonocytic Leuekmia (CMML), atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), and Myelodysplastic & Myeloproliferative Neoplasm Unclassifiable (MDS/MPN-U). Click here to learn more or see if you are eligible to participate. https://www.youtube.com/watch?v=ReJoZW5bPpg
When Jody Winsick-Soluri was diagnosed with acute lymphoblastic leukemia (ALL), she found out she had a chromosomal abnormality, the Philadelphia chromosome, which made her prospects bleak. “I was bleeding out; they said I might only have 24 hours to live,” Winsick-Soluri remembers. Now, after many rounds of chemotherapy, total body irradiation, two bone marrow transplants…
Frontline treatment with CPX-351 (Vyxeos) significantly boosted overall survival (OS) for older patients with high-risk, secondary acute myeloid leukemia (AML) when compared with the current standard of care, cytarabine and daunorubicin, according to data from a phase III trial released by the drug’s developer, Celator Pharmaceuticals, Inc. “These findings confirm that Vyxeos provides the first opportunity…
Dr. Ritchie provides and in-depth look at what it takes to diagnose MDS. For more information visit crushdmds.org. https://www.youtube.com/watch?v=oSIo2oLi3tA
Dr. Desai discusses approved treatments for intermediate and high risk MDS. For more information visit crushmds.org. https://www.youtube.com/watch?v=6Wcns91EHR4
Joint Effort Expands Experts’ Capacity to Develop Treatments, Find a Cure Ex-marine Kevin Chambers had always been a strong and powerfully built man. The retired 66-year-old Vietnam War veteran used to work as a professional bodyguard in New York City, providing personal security for major celebrities like Michael Jackson, James Cagney and Barbra Streisand. Last…
Following are conferences conducted by AAMDS afford you the opportunity to meet top experts and fellow patients at a free program near you: Living with Aplastic Anemia, MDS, and PNH Washington, D.C. Saturday, March 19, 2016 8:30a to 4:30p For location and registration Cincinnati, OH Saturday, April 30, 2016 8:30a to 4:30p For location and registration…
Are you or a loved one affected by aplastic anemia, MDS (myelodysplastic syndromes), PNH (paroxysmal nocturnal hemoglobinuria), or PRCA (pure red cell aplasia)? This special week corresponds with the National Organization for Rare Disorders (NORD)’s Rare Disease Day, which is held on February 29. For more information please visit AAMDS
Seeking Research Volunteers – Predicting Response To Your Myelodysplastic Syndrome (MDS) Treatment
Dr. Roboz discusses “The Patient’s Playbook,” a new book that will help patients navigate our health care system. Click here to view the video.
Calling all north east patients and family members. AAMDS is holding a conference on Saturday, September 19 in Boston. For more information please visit the AAMDS website
Collaboration Will Focus on Improving Patient Outcomes in AML Using Targeted Cellular Therapy Developed by Cellectis June 02, 2015 05:00 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Regulatory News: “Cellectis has interesting preclinical data on UCART123 and our alliance will seek to build on these findings to better understand the clinical potential of this therapy. Our…
The Weill Cornell Leukemia Program has recently opened a new clinical trial for men and women who have been diagnosed with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMMoL) . The study sponsor is TetraLogics Pharmaceuticals and the principal investigator at Weill Cornell is Dr. Ellen Ritchie. For more information about the study, please call Katherine…
The Weill Cornell Leukemia Program has recently opened a new clinical trial for men and women who have been diagnosed with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The study sponsor is Tensha Therapeutics, Inc. and the principal investigator at Weill Cornell is Dr. Gail Roboz. For more information about the study, please call Tania Curcio,…
The Weill Cornell Leukemia Program has recently opened a new clinical trial for men and women who have been diagnosed with Acute Myeloid Leukemia (AML). The study sponsor is Karyopharm Therapeutics and the principal investigator at Weill Cornell is Dr. Gail Roboz. For more information about the study, please call Tania Curcio, RN at (212) 746-2571…
When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what’s ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases. “AML continues to languish at the bottom of the survival curve. The lymphoid diseases are just doing so…
Dr. Gail Roboz, an associate professor of medicine, was elected chair of the 2014 American Society of Hematology Leukemia Education Session, which will take place during the society’s annual meeting in December in San Francisco. The meeting allows attendees to review more than 3,000 scientific abstracts and access a community of more than 20,000 international…
On Saturday, May 17, Dr. Gail Roboz will speak at a free interactive conference in Philadelphia for patients and families living bone marrow failure diseases http://bit.ly/1jaCJan The conference is sponsored by the Aplastic Anemia & MDS International Foundation (AA&MDSIF). If you’re in the Philadelphia area from 8:30a to 5p please join Dr. Roboz and other…
Watch Dr. Gail Roboz’s appearance on Good Morning America with Robin Roberts, where she discusses bone marrow transplants for leukemia and myelodysplastic syndrome (MDS). She also mentions CRUSH!!MDS http://www.crushmds.org/, a comprehensive clinical database initiated by Dr Roboz, M.D. on behalf of the MDS Clinical Research Consortium. The segment with Dr. Roboz starts with 4 minutes…
To view the entire presentation and slideshow, click here.
Dr. Gail Roboz was interviewed by People Magazine about bone marrow donation and transplant. To read the article click here.
An April 21, 2013 article in the New York Times describes the budding field of Precision Medicine. The article highlights Weill Cornell’s state-of-the-art Cancer Center and how Precision Medicine is being used to treat patients with Leukemia. To read the full article, click here.
Dr. Gail Roboz was interviewed and photographed alongside Good Morning America anchor and her bone marrow transplant doctor on March 31, 2013. To read the full article, click here.
Leukemia Program Nurse Practitioner, Sandy Allen-Bard, moderated a Medscape Eduation program titled, The Nurse View: Common Clinical Challenges and Best Practices in Chronic Myeloid Leukemia. The view the program (which requires that you create a free Medscape account), click here.
Leukemia Program Director, Gail Roboz, M.D. interviewed on ABC’s 20/20. To watch the interview, click here. To read the related article, click here.
To view the interview, click here.
To view the interview, click here.
To view the video, click here.
Dr. Gail Roboz was interviewed Tuesday, November 20th about Myelodysplastic Syndrome. Watch the interview below.
To see the interview, click here.
To view the interview, click here.
Dr. Gail Roboz interviewed about bone marrow transplants on Good Morning America. To view the interview, click here.
To view the video, click here.
To see the interview, click here.
New Translational Research Grants Awarded to Accelerate Promising Blood Cancer Research Discoveries from the Laboratory to the Patients’ Bedside. Read the press release here. For more information on the Leukemia and Lymphoma Society, click here. For information on the Guzman Lab and the research of Monica Guzman, PhD, click here. For information on the laboratory…
NewYork-Presbyterian/Weill Cornell Medical Center is 1 of 6 institutions selected to participate in new MDS clinical research consortium NEW YORK (June 18, 2012) — NewYork-Presbyterian/Weill Cornell Medical Center is one of six institutions selected to join the newly-founded MDS Clinical Research Consortium. The Consortium’s mission is to significantly advance treatments and patient outcomes for Myelodysplastic…
Six academic medical centers, including Weill Cornell Medical College, have set up the first privately funded consortium in the US to focus on clinical trials and research for patients with myelodysplastic syndrome (MDS). The MDS Clinical Research Consortium is a five-year, $16 million initiative sponsored by the Aplastic Anemia & MDS International Foundation and supported…
The Weill Cornell Leukemia Program is now recruiting patients for a new study, “CALGB 10801: A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib and Continuation Therapy with Dasatinib Alone in Newly Diagnosed Patients with Core Binding Factor Acute Myeloid Leukemia (AML).” The physician leading the study at Weill Cornell…
Dr. Gail Roboz spoke with ecancertv at ASH 2011 in San Diego about the major genomic research on acute myeloid leukaemia. There has been a lot of recent success on identifying mutations and abnormalities in AML; however, Prof Roboz believes that the discovery period with genomic research is coming to an end and a move…
Two Leukemia Program physicians, Dr. Gail Roboz and Dr. Karen Carlson were asked to speak at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego. Leukemia Program Director, Dr. Gail Roboz, gave a presentation titled, “Novel Approaches to the Treatment of AML” during the “Acute Myeloid Leukemia in the Age of Genomics”…
http://www.youtube.com/watch?v=jQrzdmvpgHg Check out Dr. Melnick on YouTube describing his experience at Weill Cornell.
On September 23 New York Governor Andrew Cuomo signed into law a bill that requires health plans to cover orally administered chemotherapy treatments at a cost equal to intravenously or injected chemotherapy treatments. The bill will go into effect January 2012. Traditional intravenous chemotherapy drugs administered in a hospital or clinic are often included as…
Two NewYork-Presbyterian-Weill Cornell Medical Center patients and their families held a fundraiser on Staten Island to help other patients with leukemia. The patients met when they were receiving treatment at NYP/Weill Cornell. Click the image below to watch the video on NY1.
Leukemia Program Nurse, Sandra Allen-Bard, contributed to an informational video on Chronic Myeloid Leukemia. To view it, click here.
The work of Drs. Ritchie, Roboz, Scandura, Gergis, and Feldman, and nurse Tania Curcio was presented at the 2009 American Society of Clinical Oncology Annual Meeting. The presentation focused on a clinical trial treating elderly AML and high-grade MDS patients. To view the presentation, click here.
Check out this video interview of Dr. Roboz about Lenalidomide for intermediate and low-grade MDS. Click here to view.
Dr. Gail Roboz contributed to a comprehensive newsletter highlighting developments at the recent 2011 ASCO Annual Meeting. To view the newsletter and get updates on AML, ALL, Myelofibrosis, and more, click here.
To view Dr. Roboz’s presentation, click here.
Click the image to view the presentation.
Dr. Ritchie discusses the treatments available for acute leukemias.
Sandra Allen-Bard, BSN, MSN, AOCNP, ANCC has won the Leukemia and Lymphoma Society’s (LLS) National Chairman’s Citation for 2011. This is the second Chairman’s Citation for Ms. Allen-Bard, who was also recognized for her outstanding contributions by LLS in 2009. The Chairman’s Citation recognizes the outstanding accomplishments of individuals who have demonstrated significant dedication and…
Gail J. Roboz, MD, Director of the Weill Cornell Leukemia Program, explains how unexplained bruises can affect your health. Click here to view the video.
Dr. Gail Roboz talks about Myelodysplastic Syndrome treatment issues for the Aplastic Anemia & MDS International Foundation’s Interviews with the Experts. Click the image to the left to read the interview.
Gail Roboz, MD, Director of the Weill Cornell Leukemia Program, gave a presentation on Acute Myeloid Leukemia in older patients at the American Society of Clinical Oncology annual meeting in 2009. Click here to listen to Dr. Roboz’s presentation.
The purpose of this study is to evaluate the effectiveness and side-effects of an intensive program using multiple chemotherapy drugs that has been designed for children but is now being used in young adults up to age 40. We hope to improve the outcome of adolescents and young adults with acute lymphoblastic leukemia (ALL). We…
Weill Cornell Leukemia Program 